182 related articles for article (PubMed ID: 20934559)
1. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease.
White H; Held C; Stewart R; Watson D; Harrington R; Budaj A; Steg PG; Cannon CP; Krug-Gourley S; Wittes J; Trivedi T; Tarka E; Wallentin L
Am Heart J; 2010 Oct; 160(4):655-61. PubMed ID: 20934559
[TBL] [Abstract][Full Text] [Related]
2. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
3. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque.
Serruys PW; García-García HM; Buszman P; Erne P; Verheye S; Aschermann M; Duckers H; Bleie O; Dudek D; Bøtker HE; von Birgelen C; D'Amico D; Hutchinson T; Zambanini A; Mastik F; van Es GA; van der Steen AF; Vince DG; Ganz P; Hamm CW; Wijns W; Zalewski A;
Circulation; 2008 Sep; 118(11):1172-82. PubMed ID: 18765397
[TBL] [Abstract][Full Text] [Related]
4. Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome.
O'Donoghue ML; Braunwald E; White HD; Serruys P; Steg PG; Hochman J; Maggioni AP; Bode C; Weaver D; Johnson JL; Cicconetti G; Lukas MA; Tarka E; Cannon CP
Am Heart J; 2011 Oct; 162(4):613-619.e1. PubMed ID: 21982651
[TBL] [Abstract][Full Text] [Related]
5. Darapladib for preventing ischemic events in stable coronary heart disease.
; White HD; Held C; Stewart R; Tarka E; Brown R; Davies RY; Budaj A; Harrington RA; Steg PG; Ardissino D; Armstrong PW; Avezum A; Aylward PE; Bryce A; Chen H; Chen MF; Corbalan R; Dalby AJ; Danchin N; De Winter RJ; Denchev S; Diaz R; Elisaf M; Flather MD; Goudev AR; Granger CB; Grinfeld L; Hochman JS; Husted S; Kim HS; Koenig W; Linhart A; Lonn E; López-Sendón J; Manolis AJ; Mohler ER; Nicolau JC; Pais P; Parkhomenko A; Pedersen TR; Pella D; Ramos-Corrales MA; Ruda M; Sereg M; Siddique S; Sinnaeve P; Smith P; Sritara P; Swart HP; Sy RG; Teramoto T; Tse HF; Watson D; Weaver WD; Weiss R; Viigimaa M; Vinereanu D; Zhu J; Cannon CP; Wallentin L
N Engl J Med; 2014 May; 370(18):1702-11. PubMed ID: 24678955
[TBL] [Abstract][Full Text] [Related]
6. Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease.
Riley RF; Corson MA
IDrugs; 2009 Oct; 12(10):648-55. PubMed ID: 19790016
[TBL] [Abstract][Full Text] [Related]
7. Darapladib.
Bui QT; Wilensky RL
Expert Opin Investig Drugs; 2010 Jan; 19(1):161-8. PubMed ID: 20001561
[TBL] [Abstract][Full Text] [Related]
8. Utility of Lp-PLA2 in lipid-lowering therapy.
Racherla S; Arora R
Am J Ther; 2012 Mar; 19(2):115-20. PubMed ID: 20634673
[TBL] [Abstract][Full Text] [Related]
9. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.
O'Donoghue ML; Braunwald E; White HD; Lukas MA; Tarka E; Steg PG; Hochman JS; Bode C; Maggioni AP; Im K; Shannon JB; Davies RY; Murphy SA; Crugnale SE; Wiviott SD; Bonaca MP; Watson DF; Weaver WD; Serruys PW; Cannon CP; ; Steen DL
JAMA; 2014 Sep; 312(10):1006-15. PubMed ID: 25173516
[TBL] [Abstract][Full Text] [Related]
10. Darapladib: an emerging therapy for atherosclerosis.
Corson MA
Ther Adv Cardiovasc Dis; 2010 Aug; 4(4):241-8. PubMed ID: 20660537
[TBL] [Abstract][Full Text] [Related]
11. Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes.
Rosenson RS
Curr Opin Lipidol; 2010 Dec; 21(6):473-80. PubMed ID: 20739882
[TBL] [Abstract][Full Text] [Related]
12. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.
Cannon CP; Dansky HM; Davidson M; Gotto AM; Brinton EA; Gould AL; Stepanavage M; Liu SX; Shah S; Rubino J; Gibbons P; Hermanowski-Vosatka A; Binkowitz B; Mitchel Y; Barter P;
Am Heart J; 2009 Oct; 158(4):513-519.e3. PubMed ID: 19781408
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
[TBL] [Abstract][Full Text] [Related]
14. Chronic inhibition of lipoprotein-associated phospholipase A
Prasad M; Lennon R; Barsness GW; Prasad A; Gulati R; Lerman LO; Lerman A
Int J Cardiol; 2018 Feb; 253():7-13. PubMed ID: 29306475
[TBL] [Abstract][Full Text] [Related]
15. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
Sabatine MS; Morrow DA; O'Donoghue M; Jablonksi KA; Rice MM; Solomon S; Rosenberg Y; Domanski MJ; Hsia J;
Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2463-9. PubMed ID: 17766330
[TBL] [Abstract][Full Text] [Related]
16. Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study.
Vedin O; Hagström E; Stewart R; Brown R; Krug-Gourley S; Davies R; Wallentin L; White H; Held C
Eur J Prev Cardiol; 2013 Aug; 20(4):678-85. PubMed ID: 22496275
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.
Wallentin L; Held C; Armstrong PW; Cannon CP; Davies RY; Granger CB; Hagström E; Harrington RA; Hochman JS; Koenig W; Krug-Gourley S; Mohler ER; Siegbahn A; Tarka E; Steg PG; Stewart RA; Weiss R; Östlund O; White HD;
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27329448
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
Robins SJ; Collins D; Nelson JJ; Bloomfield HE; Asztalos BF
Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1172-8. PubMed ID: 18356553
[TBL] [Abstract][Full Text] [Related]
19. Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.
Dosh K; Berger PB; Marso S; van Lente F; Brennan DM; Charnigo R; Topol EJ; Steinhubl S
Circ Cardiovasc Interv; 2009 Dec; 2(6):503-12. PubMed ID: 20031767
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker.
Toth PP; McCullough PA; Wegner MS; Colley KJ
Expert Rev Cardiovasc Ther; 2010 Mar; 8(3):425-38. PubMed ID: 20222820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
